

# Beslut vid Fru Berta Kamprads styrelsemöte 21 april 2020

## **Bo Baldetorp, FBKS-2020-2**

*Flow cytometric DNA ploidy and S-phase fraction as prognostic factors in FIGO stage I endometrial carcinoma and its relation to other clinical and tumor biological factors. - Multicentric study based on metaanalysis of Clinical and laboratory data. - Quantitative proteomic analysis of proliferative cell biological factors.*

Anslag beviljat: 2020-2021

## **Helena Jernström, FBKS-2020-4**

*Interactions between dietary supplements and irradiation in different types of breast cancer, the good, the bad, and the ugly*

Anslag beviljat: 2020-2021

## **Johan Staaf, FBKS-2020-5**

*At the crossroad of DNA repair deficiency and immune response in triple negative breast cancer*

Anslag beviljat: 2020-2023

## **Mattias Belting, FBKS-2020-6**

*Translational studies in oncology using integrated high-resolution tissue mapping and single cell laser capture microdissection: A joint infrastructure application for the Kamprad site*

Anslag beviljat: 2020-2023

## **Maria Planck, FBKS-2020-7**

*Clinical studies for improved targeted therapy in non-small cell lung cancer*

Anslag beviljat: 2020-2023

## **Anna Sundlöv, FBKS-2020-8**

*START-NET: Systemic Targeted Adaptive Radiotherapy for Neuroendocrine Tumors - An international, multicentre, phase III clinical trial*

Anslag beviljat: 2020-2023

## **Siker Kimbung, FBKS-2020-9**

*Early prognostic and treatment predictive biomarkers for individualizing preoperative chemotherapy treatment in breast cancer.*

Anslag beviljat: 2020-2021

## **Håkan Olsson, FBKS-2020-10**

*Use of the antihistamine, desloratadine and to a lesser degree loratadine, improves survival in a number of cancer forms*

Anslag beviljat: 2020-2021

**Karin Jirström, FBKS-2020-11**

*Genetic topography and tumour immunogenicity of pancreatic and other periampullary cancers. The CHAMP study*

Anslag beviljat: 2020-2022

**Carlos Rovira, FBKS-2020-12**

*Utveckling av RNA-inriktade läkemedel för cancerbehandling*

Anslag beviljat: 2020-2021

**Katarina Sjögreen Gleisner, FBKS-2020-13**

*Tumour dosimetry and dose planning of <sup>177</sup>Lu-DOTA-TATE treatment*

Anslag beviljat: 2020-2023

**Sandra Lindstedt, FBKS-2020-14**

*Diagnos with a breath - A new non-invasive diagnosis method for lungcancer*

Anslag beviljat: 2020-2021

**Elsa Arbajian, FBKS-2020-15**

*A combined clinical, molecular and computational approach to Lung cancer classification and treatment monitoring.*

Anslag beviljat: 2020-2021

**Crister Ceberg, FBKS-2020-17**

*Annual conference of the European Radiation Research Society - ERRS2020 in Lund, Sept 13-17, 2020*

Anslag beviljat: 2020

**Yonghyo Kim, FBKS-2020-18**

*Identification of novel key regulating proteins related to tumor progression within heterogeneous malignant melanoma*

Anslag beviljat: 2020

**Gabriel Adrian, FBKS-2020-19**

*Predictive markers for individualized radiotherapy to avoid and exploit radioresistance*

Anslag beviljat: 2020-2021

**Gabriella Honeth, FBKS-2020-20**

*Identifying novel targets for therapeutic interventions in endocrine-resistant metastatic breast cancer*

Anslag beviljat: 2020-2021

**Lisa Rydén, FBKS-2020-21**

*Towards optimal selection of systemic therapy in metastatic breast cancer by integrating information from molecular profiles and liquid biopsies*

Anslag beviljat: 2020-2021

**Melinda Rezeli, FBKS-2020-22**

*VESSEL CO-OPTION IN PRIMARY VERSUS METASTATIC TUMORS*

Anslag beviljat: 2020-2021

**Magnus Tägil, FBSK-2020-23**

*The Trojan horse, an ally within a cancerous tumor. Attracting systemically circulating bone-seeking cytostatics using injectable synthetic hydroxyapatite as a recruiting platform*

Anslag beviljat: 2020-2021

**Crister Ceberg, FBKS-2020-24**

*Translational image-guided radiotherapy continued support*

Anslag beviljat: 2020-2021

**Emelie Karnevi, FBSK-2020-25**

*PODXL as a predictor of response to targeted therapies in colorectal cancer*

Anslag beviljat: 2020-2021

**Maria Gebre-Medhin, FBKS-2020-26**

*ARTSCAN III - A randomized multicenter phase III study of cisplatin plus radiotherapy compared to cetuximab plus radiotherapy in locally advanced head and neck cancer*

Anslag beviljat: 2020-2021

**Lao Saal, FBKS-2020-27**

*Continued translational development of ctDNA monitoring to improve cancer survival*

Anslag beviljat: 2020-2021

**Carina Bernardo, FBKS-2020-28**

*Molecular analyses of urothelial carcinoma plasticity and metastasis*

Anslag beviljat: 2020-2021

**Signe Borgquist, FBKS-2020-29**

*PROTECT women by PReventiOn and early detection of breast cancer initiation - cellular and molecular effects of reducing breast density*

Anslag beviljat: 2020-2023

**Jenny-Maria Jönsson, FBKS-2020-31**

*Homologous recombination repair deficiency and prediction of treatment response in serous endometrial cancer*

Anslag beviljat: 2020-2021

**Anders Wittrup, FBKS-2020-33**

*Overcoming barriers to nucleic acid therapeutics in glioblastomas*

Anslag beviljat: 2020-2023

**Helga Hagman, FBKS-2020-34**

*Customizing novel and established treatment strategies for improving outcome in metastatic colorectal cancer*

Anslag beviljat: 2020-2021